Diabetic patients with essential hypertension treated with amlodipine: Blood pressure and arterial stiffness effects of canagliflozin or perindopril

Journal of Hypertension

Volumn 37, Issue 3, 2019, Pages 636-642

  Ramirez, Agustin J ^a   Sanchez, Maria J ^a   Sanchez, Ramiro A ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Arterial hypertension; Canaglifozin; Central blood pressure; Pulse wave velocity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANAGLIFLOZIN; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PERINDOPRIL; POTASSIUM; SODIUM; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CAROTID-FEMORAL PULSE WAVE VELOCITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SODIUM URINE LEVEL; TREATMENT DURATION; COMPLICATION; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOLOGY;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; ESSENTIAL HYPERTENSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERINDOPRIL; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VASCULAR STIFFNESS;

EID: 85060941123     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001907     Document Type: Article

References (35)

1. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): Clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48:643-648.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
3. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
4. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al., The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH), of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-1357.
5. James PA, Oparil S, Carter BL, Cushman CW, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
6. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther 2014; 5:355-366.
7. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007; S27-S35.
8. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal NA /d-glucose co-transporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011; 300:C14-C21.
9. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. BMJ Open 2016; 6:e009417.
10. Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose co-transporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol 2017; 18:23.
11. Van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol 2017; 12:700-710.
12. Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab 2017; 43:99-109.
13. Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 2016; 68:1355-1364.
14. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose co-transporter 2inhibitorsin the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 34:752-772.
15. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55:1318-1327.
16. Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G, et al. Early vascular ageing in translation: From laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens 2013; 31:1517-1526.
17. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: A systemic meta-analysis. Heart Fail Rev 2015; 20:291-303.
18. Armentano R, Graf S, Ramirez AJ, Espinosa JD, Brandani L, Baglivo H, Sánchez R. Mechanical vs. intrinsic components in the improvement of brachial arterial compliance. Medicina (Buenos Aires) 2001; 61:535-540.
19. Kiuchi S, Hisatake S, Kawasaki M, Hirashima O, Kabuki T, Yamazaki J, Ikeda T. Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness. Clin Pharmacol 2015; 7:97-102.
20. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 9:13-28.
21. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17:1180-1193.
22. Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, et al. A new oscillometric method for pulse wave analysis: Comparison with a common tonometric method. J Hum Hypertens 2010; 24:498-504.
23. Weber T, Wassertheurer S, Rammer M. Blood pressure validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension 2011; 58:825-832.
24. Diaz A, Tringler M, Galli C, Ramirez A, Cabrera Fischer EI. Arterial stiffness in a rural population of Argentina: Pilot study. High Blood Press Cardiovasc Prev 2015; 22:403-409.
25. Christen A, Amentano RL, Miranda A, Graf S, Santana DB, Zócalo Y, et al. Arterial wall structure and dynamics in type 2 diabetes mellitus. Methodological aspects and pathophysiological findings. Curr Diab Rev 2010; 6:367-377.
26. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13:669-672.
27. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14:539-545.
28. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ, EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38:420-428.
29. Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: A post hoc analysis. Cardiovasc Diabetol 2017; 16:29.
30. Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, et al. Reductions in mean 24-h ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 2016; 18:43-52.
31. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomized, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4:211-220.
32. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31:1731-1768.
33. Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study. Cardiovasc Diabetol 2017; 16:138-146.
34. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16:1087-1095.
35. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al., CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644-657.